Summary: Author Bill Alpert of Barron’s contrasts MAPS’ leading non-profit and public benefit models with the profit-oriented approach of new psychedelic companies. “None of the for-profits are talking about drug policy reform,” highlights MAPS Founder and Executive Director Rick Doblin, Ph.D.
Learn about the results of our first Phase 3 trial of MDMA-assisted therapy for PTSD in the context of MAPS’ decades-long efforts to advance psychedelic science.
Originally appearing here.
